Regeneron's Five-Year Phase 3 Trial Shows Durable Survival Benefit Of Libtayo In PD-L1 High NSCLC
10/9 05:25
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced that the five-year results from the Phase 3 EMPOWER-Lung 1 trial demonstrated the durable survival benefit and impressive efficacy of first-line Libtayo monotherapy compared to chemotherapy in patients with PD-L1 high, a...